Studiencode: CE1250_5002_EU
| Institution: | CSL Behring GmbH | ||
| Titel der NIS: | A European, Prospective, Non-Interventional Study to Assess Health Related Quality of Life and to Identify Key Transitional Life Events in Patients with Moderate or Severe Haemophilia A using Helixate NexGen | ||
| Ziel der NIS: | The primary objective of this non-interventional study (NIS) was to describe the Health-Related Quality of Life (HRQoL) in adolescents and adults with moderate or severe Haemophilia A using Helixate NexGen. |
||
| Ort der Durchführung: | multinational | NIS angefordert: | nein |
| Patientenanzahl insgesamt: | 78 | Anzahl Ärzte insgesamt: | 32 |
| Patientenanzahl in Deutschland: | 15 | Ärzte in Deutschland: | 6 |
| Anzeige am: | 30.04.2013 | Geplanter Beginn: | 20.01.2010 | Geplantes Ende: | 28.01.2015 |
| Angezeigtes Ende der NIS am: nicht vorhanden | |||||
| Arzneimittelbezeichnung | INN | Zulassungs-Nr. | ATC-Code | Substanzklasse |
|---|---|---|---|---|
| Helixate NexGen | Octocog alfa | EU/1/00/144/001 | B02B D02 | Antihaemorrhagics: blood coagulation factors |
| Helixate NexGen | Octocog alfa | EU/1/00/144/002 | B02B D02 | Antihaemorrhagics: blood coagulation factors |
| Helixate NexGen | Octocog alfa | EU/1/00/144/003 | B02B D02 | Antihaemorrhagics: blood coagulation factors |
| Helixate NexGen | Octocog alfa | EU/1/00/144/004 | B02B D02 | Antihaemorrhagics: blood coagulation factors |
| Helixate NexGen | Octocog alfa | EU/1/00/144/005 | B02B D02 | Antihaemorrhagics: blood coagulation factors |
